Free Shipping on orders over $150
2
Awaiting product image

BPC-157 / TB-500 — 5mg / 5mg (injectable)

$65.00

BPC-157 is a pentadecapeptide (15 amino acid sequence) derived from a protective protein found naturally in human gastric juice. In preclinical studies, it accelerates healing of

SKU: LL-BPCTB-55 Category:

Description

Overview

This research preparation combines BPC-157 and TB-500.

BPC-157 is a pentadecapeptide (15 amino acid sequence) derived from a protective protein found naturally in human gastric juice. In preclinical studies, it accelerates healing of tendons, ligaments, muscle, and gut tissue by upregulating growth hormone receptors, promoting angiogenesis, and modulating nitric oxide pathways. It acts locally with a systemic amplification effect. Human pilot data (n<30 across all studies) suggests promise for musculoskeletal and GI applications, but large-scale RCTs have not been completed. Regulatory status has changed significantly since 2022.

TB-500 is a synthetic version of a fragment of Thymosin Beta-4 (Tβ4), found in virtually all human and animal cells. IMPORTANT: TB-500 (the synthetic fragment) is distinct from TB4 (the full endogenous protein), they should not be used interchangeably. In animal models, TB-500 promotes actin regulation, accelerates healing of muscle, tendon, ligament, and cardiac tissue, and reduces inflammation. No human RCTs exist for TB-500 specifically. TB4 showed promise in a 2009 Phase 2 trial, but results have never been published. Frequently stacked with BPC-157 in practitioner protocols.

Structure & Chemistry

  • Category: SYSTEMIC REPAIR / GI HEALING
  • Molecular size: ~1.8 kDa (small peptide)

Regulatory & Research Status

  • FDA CATEGORY 2 (2023): Cannot be legally compounded in the US for commercial use, availability is restricted.
  • WADA PROHIBITED (2022): Listed under S0 Non-Approved Substances, banned in competitive sports.
  • HUMAN EVIDENCE LIMITED: Only 3 small pilot studies (<30 total participants) exist; no completed Phase 2/3 RCTs.
  • All benefits listed below are primarily from animal/in vitro studies. Human clinical confirmation is pending.
  • Dosing protocol is practitioner-derived, not established by clinical trials.
  • REGULATORY UPDATE (June 2026): On April 16, 2026, FDA convened the Pharmacy Compounding Advisory Committee (PCAC) to evaluate substances nominated for the 503A Bulk Drug Substances list (FR 2026-07361). No compound status changes affecting this substance have been published from this meeting as of June 2026. Monitor fda.gov for finalized outcomes.
  • WADA PROHIBITED: TB-500 and Thymosin Beta-4 are banned under S2 Peptide Hormones in competitive sports.
  • NO HUMAN CLINICAL TRIALS: Zero published RCTs specifically on TB-500 (the synthetic fragment).
  • TB-500 ≠ TB4: TB-500 is a synthetic fragment; Thymosin Beta-4 (TB4) is the full endogenous protein.
  • TB4 Phase 2 trial (2009): Completed but results were NEVER published, a significant data gap after 15+ years.
  • Dosing is practitioner-derived; 2024 research suggests activity may derive partly from metabolite breakdown, not direct TB4 mechanism.

Specifications

Presentation 5mg single vial
Purity >99% by HPLC
Form Lyophilized powder (reconstitute with bacteriostatic water for laboratory use)
Category SYSTEMIC REPAIR / GI HEALING
For laboratory and research use only. Not for human or animal consumption. Not approved by the FDA for any therapeutic use. No claims regarding therapeutic efficacy are made or implied. Must be 21 or older.

Reviews

There are no reviews yet.

Be the first to review “BPC-157 / TB-500 — 5mg / 5mg (injectable)”

Your email address will not be published. Required fields are marked *

Overview

This research preparation combines BPC-157 and TB-500.

BPC-157 is a pentadecapeptide (15 amino acid sequence) derived from a protective protein found naturally in human gastric juice. In preclinical studies, it accelerates healing of tendons, ligaments, muscle, and gut tissue by upregulating growth hormone receptors, promoting angiogenesis, and modulating nitric oxide pathways. It acts locally with a systemic amplification effect. Human pilot data (n<30 across all studies) suggests promise for musculoskeletal and GI applications, but large-scale RCTs have not been completed. Regulatory status has changed significantly since 2022.

TB-500 is a synthetic version of a fragment of Thymosin Beta-4 (Tβ4), found in virtually all human and animal cells. IMPORTANT: TB-500 (the synthetic fragment) is distinct from TB4 (the full endogenous protein), they should not be used interchangeably. In animal models, TB-500 promotes actin regulation, accelerates healing of muscle, tendon, ligament, and cardiac tissue, and reduces inflammation. No human RCTs exist for TB-500 specifically. TB4 showed promise in a 2009 Phase 2 trial, but results have never been published. Frequently stacked with BPC-157 in practitioner protocols.

Structure & Chemistry

  • Category: SYSTEMIC REPAIR / GI HEALING
  • Molecular size: ~1.8 kDa (small peptide)

Regulatory & Research Status

  • FDA CATEGORY 2 (2023): Cannot be legally compounded in the US for commercial use, availability is restricted.
  • WADA PROHIBITED (2022): Listed under S0 Non-Approved Substances, banned in competitive sports.
  • HUMAN EVIDENCE LIMITED: Only 3 small pilot studies (<30 total participants) exist; no completed Phase 2/3 RCTs.
  • All benefits listed below are primarily from animal/in vitro studies. Human clinical confirmation is pending.
  • Dosing protocol is practitioner-derived, not established by clinical trials.
  • REGULATORY UPDATE (June 2026): On April 16, 2026, FDA convened the Pharmacy Compounding Advisory Committee (PCAC) to evaluate substances nominated for the 503A Bulk Drug Substances list (FR 2026-07361). No compound status changes affecting this substance have been published from this meeting as of June 2026. Monitor fda.gov for finalized outcomes.
  • WADA PROHIBITED: TB-500 and Thymosin Beta-4 are banned under S2 Peptide Hormones in competitive sports.
  • NO HUMAN CLINICAL TRIALS: Zero published RCTs specifically on TB-500 (the synthetic fragment).
  • TB-500 ≠ TB4: TB-500 is a synthetic fragment; Thymosin Beta-4 (TB4) is the full endogenous protein.
  • TB4 Phase 2 trial (2009): Completed but results were NEVER published, a significant data gap after 15+ years.
  • Dosing is practitioner-derived; 2024 research suggests activity may derive partly from metabolite breakdown, not direct TB4 mechanism.

Specifications

Presentation 5mg single vial
Purity >99% by HPLC
Form Lyophilized powder (reconstitute with bacteriostatic water for laboratory use)
Category SYSTEMIC REPAIR / GI HEALING
For laboratory and research use only. Not for human or animal consumption. Not approved by the FDA for any therapeutic use. No claims regarding therapeutic efficacy are made or implied. Must be 21 or older.

Related Research

Related products